血清可溶性CD163、HO-1水平对下肢动脉硬化闭塞症介入术后再狭窄发生的预测价值  

The value of serum soluble CD163 and HO-1 levels in the prediction of occurrence of restenosis after interventional treatment of lower extremity atherosclerotic occlusive disease

作　　者：吕忠俊 时明涛[1] 李伟杰 LYU Zhongjun;SHI Mingtao;LI Weijie(Department of Vascular Surgery,Nanyang Central Hospital,Nanyang,Henan 473000,China)

机构地区：[1]南阳市中心医院血管外科,河南省南阳市473000

出　　处：《中国动脉硬化杂志》2021年第10期864-868,共5页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学青年基金项目(81800410);河南省科技攻关项目(2018020445)。

摘　　要：目的检测下肢动脉硬化闭塞症(LEAOD)患者血清可溶性血红蛋白清道夫受体(sCD163)和血红素氧合酶1(HO-1)水平,并探讨二者表达水平与患者介入术后再狭窄发生的相关性。方法选取2016年5月—2018年2月在本院血管外科收治的LEAOD并行介入治疗的患者115例作为研究对象,并根据患者复查结果是否发生再狭窄分为再狭窄组(n=47)和无再狭窄组(n=68)。采用酶联免疫吸附法(ELISA)检测各组研究对象血清sCD163、HO-1的水平;采用受试者工作特征(ROC)曲线评估血清sCD163、HO-1水平对LEAOD患者介入术后再狭窄的预测价值;采用Logistic回归分析LEAOD患者介入术后再狭窄的影响因素。结果再狭窄组血清sCD163、HO-1水平均显著高于无再狭窄组(P<0.05)。ROC结果显示,血清sCD163、HO-1诊断LEAOD患者介入术后再狭窄的AUC分别为0.863、0.736,截断值分别为660.792μg/L、15.067μg/L,对应灵敏度分别为80.9%、57.4%,特异度分别为77.9%、92.6%。血清sCD163、HO-1联合检测诊断LEAOD患者介入术后再狭窄的AUC为0.896,对应灵敏度和特异度分别为87.2%、79.4%。Logistic回归分析显示,高血清sCD163、HO-1是影响LEAOD患者介入术后再狭窄的独立危险因素。结论sCD163、HO-1在LEAOD介入术后再狭窄患者血清中的水平明显升高,两者参与LEAOD介入术后再狭窄的发生及发展,提示sCD163、HO-1可能作为LEAOD患者介入术后再狭窄的早期诊断及病情评估的潜在生物学指标。Aim To detect the levels of serum soluble cluster differentiation 163(sCD163)and heme oxygenase-1(HO-1)in patients with lower extremity atherosclerotic occlusive disease(LEAOD),and to explore the correlation between the levels of sCD163,HO-1 and restenosis after intervention.Methods From May 2016 to February 2018,115 patients with LEAOD who were given interventional therapy in the Vascular Surgery Department of Nanyang Central Hospital were selected as the study object.According to the reexamination results,they were divided into two groups:restenosis group(n=47)and non restenosis group(n=68).Enzyme linked immunosorbent assay(ELISA)was used to detect the levels of serum sCD163 and HO-1 in each group.Receiver operating characteristic(ROC)curve was used to evaluate the predictive value of serum sCD163 and HO-1 levels for restenosis in patients with LEAOD,and Logistic regression was used to analyze the influencing factors of restenosis in patients with LEAOD.Results The levels of serum sCD163 and HO-1 in restenosis group were significantly higher than those in non restenosis group(P<0.05).The results of ROC showed that the AUC of serum sCD163 and HO-1 in the diagnosis of restenosis after LEAOD was 0.863 and 0.736 respectively,and the cut off value was 660.792μg/L and 15.067μg/L respectively,at this time,the corresponding sensi-tivity was 80.9%and 57.4%respectively,and the specificity was 77.9%and 92.6%respectively.The AUC of serum sCD163 combined with HO-1 in the diagnosis of restenosis after LEAOD was 0.896,and the corresponding sensitivity and specificity were 87.2%and 79.4%,respectively.Logistic analysis showed that the high levels of serum sCD163 and HO-1 were independent risk factors for restenosis after LEAOD intervention.Conclusion The levels of sCD163 and HO-1 in serum of patients with restenosis after LEAOD intervention are significantly increased,and both of them par-ticipate in the occurrence and development of restenosis after LEAOD intervention,suggesting that sCD163 and HO-1 may be potential biologic

关 键 词：可溶性血红蛋白清道夫受体 血红素氧合酶1 下肢动脉硬化闭塞症 介入术后再狭窄 预测价值 

分 类 号：R5[医药卫生—内科学]